AI and Cancer Research ── Lung ── 2026-11-19
Lung cancer: treatment, trials and AI
- Abstract
AbstractAI models using medical images are increasingly proposed to support clinical decision-making in lung cancer, motivating assessment of their methodological rigor and transparency. To assess how these models are developed, evaluated, and reported, and to identify gaps in best statistical practices, we conducted a cross-sectional meta-research review of OpenAlex-indexed studies (January 1, 2023, to June 30, 2025) that developed image-based AI tools for lung cancer risk prediction, detection, or prognosis. Thirty-six studies met our inclusion criteria. Convolutional neural networks were used in most studies (27 studies, 75%), and area under the curve (AUC) was the most frequently reported evaluation metric (29 studies, 81%). Although 23 studies (64%) reported some form of uncertainty quantification, most were limited to presenting confidence intervals for global performance metrics (e.g., AUC, sensitivity, and accuracy) rather than individual prediction- or risk-level uncertainty. Common limitations included limited external test set use (14 studies, 39%), insufficient subgroup analyses (10 studies, 28%), and limited adherence to established prediction-model reporting guidelines. Overall, future research should prioritize standardized reporting, use of external test sets, and model performance assessment across clinically relevant subpopulations. The coexistence of increasingly powerful AI-based prediction models with inconsistent study design, evaluation, and reporting practices emphasizes the urgent need to implement more rigorous and transparent methodological standards in this field. (Funded by Yale School of Public Health.).
Journal IF-equivalent: 27.2 (OpenAlex 2-year mean citedness, value as of 2026-11-16, retrieved 2026-11-18; not the official Clarivate IF)Reference: Hou Y, Ward T, Yang CH, McGrath S, Jernigan E, Caturegli G, et al. A Meta-Research Review of Statistical Practices for Image-Reliant AI Tools Predicting Lung Cancer Outcomes. NEJM AI. 2026 Nov 16 [Epub ahead of print]. doi:10.1056/aira2600064. PMID: 43037489.Checked: Abstract only - Abstract
RATIONALE: Chronic obstructive pulmonary disease (COPD) affects 40-60% of non-small cell lung cancer (NSCLC) patients but remains frequently underdiagnosed and undertreated, contributing to adverse outcomes [1]. METHODS: Our objective was to develop an automated machine learning (ML) classifier to identify potential COPD, and potentially untreated COPD among NSCLC patients. We performed a retrospective cohort study of 4,604 NSCLC patients. Manual chart review (development set; DS; [n = 600]; test set; TS; [n = 294]), using Global Initiative for Obstructive Lung Disease (GOLD) criteria, served as the reference standard for COPD diagnosis. Predictor selection used least-absolute-shrinkage-and-selection-operator (LASSO) logistic regression. Two logit thresholds were chosen to create binary classifiers: a ≥ 95% specificity quality-improvement threshold (QIT) for COPD identification, and Youden's index threshold (YT) for survival analysis and association with radiographic emphysema. RESULTS: The classifier achieved an area-under-the-receiver-operating-characteristic-curve of 0.93 in the DS and TS (95% CI:0.91-0.95; 95% CI:0.91-0.96, respectively). The QIT yielded logit cutoffs ≥ 0.9242 (DS) and ≥ 0.9625 (TS), with sensitivities 69% and 72%, specificities 95% and 96%, positive-predictive-value (PPV) 93%, and negative-predictive-value (NPV) 77% and 80%, respectively. In the DS and TS, potential COPD prevalence was 48% and 46%, with 41% and 46% potentially untreated; the QIT-classifier identified 69% and 72% of potential COPD cases and 40% and 50% of potentially untreated cases, respectively (PPV 85%, 95% CI:73-93% and 86%, 95% CI:71-95%). YT yielded a sensitivity and specificity of 88%. In Cox-proportional hazards models (n = 4,501, 1,959 deaths), the YT-COPD classifier was associated with increased mortality, with significant effect measure modification by clinical stage (p = 0.003; stratified HR YT-COPD: stage I: 1.71, 95% CI:1.30-2.44, p < 0.001; Stage II: 1.72, 95% CI:1.15-2.59, p = 0.009; Stage III: 1.67, 95% CI:1.34-2.08, p < 0.001; Stage IV: 1.29, 95% CI:1.15-1.44, p < 0.001). Furthermore, classifier-predicted COPD (YT) was strongly associated with radiographic emphysema (p < 0.001). CONCLUSION: This ML classifier effectively emulates structured chart review to identify potential COPD and potentially untreated COPD in NSCLC, with prognostic validity and potential for scalable, low-cost quality improvement and research. External validation in other institutions and EHR systems is warranted before broader implementation.
Journal IF-equivalent: 3.4 (OpenAlex 2-year mean citedness, value as of 2026-11-11, retrieved 2026-11-12; not the official Clarivate IF)Reference: Halawa AR, Robles SE, Ferguson J, Young C, Sainz PV, Lu SC, et al. Development of an automated machine learning classifier for chronic obstructive pulmonary disease in non-small cell lung cancer patients using electronic health records. BMC Pulm Med. 2026 Aug 21;26(1):573. doi:10.1186/s12890-026-04448-z. PMID: 43040280.Checked: Abstract only